Alpha Tau Medical Study update
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning. Thank you, everybody, for joining us this morning to talk about the newest Alpha DaRT results coming out of our REGAIN study for recurrent glioblastoma. We are thrilled to be here this morning together to discuss the results that were just presented at the annual meeting of the Society for Neuro-Oncology in Philadelphia over the weekend. Today, I'm joined by Uzi Sofer, our CEO, Dr. Robert Den, our Chief Medical Officer, and Dr. Joshua Palmer, who is a Professor of Radiation Oncology at the James at Ohio State University, as well as Principal Investigator of the REGAIN study. Today, what we're going to do is we're going to review the mechanism of the Alpha DaRT in a quick refresher. We'll move into the results that were discussed and released over the weekend, the interim results from the REGAIN trial.
We'll look at a patient-by-patient overview, and then leave time at the end for a summary and for questions and answers. With that, I'll turn it over to my colleague, Dr. Den, to do a quick refresh of the Alpha DaRT mechanism.
Thank you, Raphi, very much. It's a pleasure to be with all of you this morning. I just want to provide a refresher to bring everyone on the same page, understanding exactly how the Alpha DaRT work and what makes it unique. Why do we focus on alpha radiation? Alpha radiation has two major advantages to standard beta or gamma radiation. While all three types of radiation damage the DNA and by which cause cancer cell death, alphas are unique in that they work independently of oxygen, and this is particularly crucial when we think about diseases like recurrent GBM, which is known pathognomonically to have necrosis, meaning that there is areas of lack of oxygen.
The second major advantage that the alpha radiation has versus beta or gamma radiation is that it causes irreparable double-strand DNA breaks at a much higher threshold, which leads to the cells undergoing various forms of cell death. On the safety side, alphas are quite unique in that they can be stopped by something as thin as a sheet of paper. What this means is that we are able to do our procedures safely in standard operating rooms throughout the world. We do not require that physicians doing the procedure wear any protective lead shielding, and so therefore, we have minimized potential barrier to entry or adoption by the physician staff. Furthermore, the alpha particles themselves have a limitation, which is that they have a very narrow range in tissue and can only travel between 40 to 90 microns.
What that means is that if we were to use a source which releases alpha particles directly, we would have no range. In order to overcome this issue, we have designed what we call the Alpha DaRT. DaRT stands for Diffusing Alpha-emitters Radiation Therapy. Essentially what we do is we take a thin titanium seed and we coat it with a radioactive atom, radium-224, which undergoes radioactive decay, and through this decay process, releases its daughter atoms directly into the tumor. These daughter atoms then carry the subsequent alpha decays further and further away from the placement of the seed itself. Here we can see this on a video where we are- Revolutionary alpha emitters radiotherapy, the Alpha Radial Applicator.
Current treatments of brain tumors still provide results with a poor prognosis. Alpha Tau has developed the Alpha Radial Applicator, which is designed to distribute the Alpha DaRT sources in a precise spacing while potentially minimizing the damage to the brain. How it is used. A stereotactic- Is our seed.
I want to now show you how we actually deliver the- Revolutionary alpha emitters radiotherapy, the Alpha Radial Applicator.
Current treatments of brain tumors still provide results with a poor prognosis. Alpha Tau has developed the Alpha Radial Applicator, which is designed to distribute the Alpha DaRT sources in a precise spacing while potentially minimizing the damage to the brain. How it is used. A stereotactic navigation biopsy needle is inserted into the brain until it reaches the desired depth and location. The Alpha Radial Applicator is affixed to the biopsy needle hub. The physician opens the needle's window and pushes the flexible applicator tube into the tumor. Once the tube is in place, the physician pushes the stylet forward and retracts the tube. Once the source is deployed, the needle is rotated to the next position. This way, a layer of Alpha DaRT sources is evenly distributed around the needle without the need to reinsert the needle repeatedly.
After the first layer of sources has been inserted, the biopsy needle and the applicator are drawn upwards to deploy the next layer of sources, as may be necessary per the relevant treatment plan. At the end of the procedure, the biopsy needle and the applicator are removed, while the Alpha DaRT sources are designed to remain in the tumor and release alpha emitters into the tumor. The alpha emitters diffuse into the tumor and emit alpha radiation, which is known to cause double-strand DNA breaks and tumor destruction. Alpha Tau, treating cancer with precision.
I have the pleasure now to turn the microphone over to Dr. Palmer to present the interim results that were just recently presented at the SNO Annual Meeting on the REGAIN trial.
Good morning, everyone. Thank you so much. We want to touch base initially on some of the trial design and some of the purpose of the prospective open-label single-arm study. The initial study design was meant for 10 patients, which has been extended to 20. We have currently treated eight patients to date, and we are going to be presenting six patients today that have reached their time to response assessment, with a planned follow-up of 12 months for each patient. The primary endpoint of the study is feasibility, so understanding the deployment of all the planned sources with the planned tumor coverage that exceeds our predefined study safety, and then serious adverse events within 90 days of the procedure. Our secondary endpoints, which we will also be presenting some of this today, is the radiographic tumor response based on RANO 2.0 and overall survival.
Eligibility for these patients, they have to be an IDH wild-type grade 4 glioma, up to three recurrences, and a tumor size under 3 centimeters. They cannot have had prior radiation therapy. The majority of these patients, or all of these patients so far to date, have had radiation in field to their area of recurrence. The treatment then includes a stereotactic intratumoral implant of these titanium sources that have been loaded with radium-224, which you have seen is the Alpha DaRT design, image-guided placement using a craniotomy and burr hole. Our interim feasibility, 100% of patients had all planned sources deployed without any unanticipated serious adverse events. Our ability to cover the tumor was, we were able to meet our primary endpoint for these patients. All 8 patients continue to be alive at the last time of follow-up, with a median follow-up of approximately seven months.
Our objective response rate was, for all 6 patients, five complete responses and one partial response, so our overall response rate being 100%. Our survival so far, again, ranges from 3 to 11.6 months. Our best overall response is assessed at the time of sort of a complete response noted on by RANO criteria. This can subsequently sort of change based on the next MRI. The best overall response continues to await confirmation in some patients as the follow-up continues to remain with just one or two MRIs. So far, there have been no recurrences in the site of treatment and one progression in a distant location away from the tumor that was implanted. We are still evaluating the necrosis or suspected necrosis in two patients, but those are asymptomatic on follow-up thus far.
For our primary feasibility, so far we have only one grade 3 serious adverse event, which was a seizure related with Todd's paralysis, which resolved with rehab and steroids. The patient is back to his original baseline. The recovery so far has been excellent in all patients. Every patient's stay has been under one day in the hospital, and the first month of the radiation delivery, there has been no additional serious adverse events. We have seen, as we have gotten patients closer to six to 12 months, we do see some radiation treatment changes, which is anticipated in these patients in retreatment. This is our plot here, so you can see where patients are in their follow-up, patients one through six.
When we look at the response assessments and the best overall responses, we have plotted here the treatment dates, the best overall response, and what was seen on their follow-up in any recurrence within the treated area. Thus far, which is sort of our most exciting component of the trial thus far, is that patients with a median follow-up of over six months have no local recurrence, which exceeds what we would expect from historical control. When we read the scans, whether it is necrosis or tumor, this is always a little bit challenging, and this is in part also added into RANO, that these patients can oftentimes, if followed for more than six to 12 months, develop treatment changes around a treatment site.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
9 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
